Review Reports

Round 1

Reviewer 1 Report

The authors comprehensively discussed the clinical impact of bevacizumab for glioblastoma treatment by reviewing previous clinical trials and other evidence, which is very informative and complete. I have no concern and recommend the acceptance of this manuscript to publish in Pharmaceuticals.

Reviewer 2 Report

This excellent review gives a good overview on the uses of BEV in glioblastoma. All relevant literature is cited, and all important aspects are discussed. This work from a Japanese group is especially interesting, as it also describes the broad Japanese eperience in using BEV in upfront therapy. Furthermore, this work gives a good overview on the many studies exploring BEV in glioblastoma. The linguistic style is very good, which makes the manuscript easy to read and understand. It has a high practical value, as many patients worldwide are still used with BEV. Furthermore, anti-angiogenic therapy might see an increased use in the future as part of a combination therapy. Especially interesting is the paragraph about the use of BEV in treating or preventing radionecrosis.

In summary, I strongly recommend publication without further changes needed.